Oscar Soto Raices, MD
Rheumatology · San Juan, PRNPI 1962441717
Payments from drug & device makers
Across 1,067 payments — averaging $2943.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly Export S.A. Puerto Rico Branch$1.7M
- AbbVie$933K
- Lilly USA, LLC$177K
- Janssen Research & Development, LLC$67K
- Eli Lilly$42K
- E.r. Squibb & Sons, L.L.C.$41K
- plus $145K from 23 others
Across 23 payments — averaging $1292.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$18K
- Eli Lilly Export S.A. Puerto Rico Branch$12K
What the payments were for
- Consulting fees$84,74524%
- Speaking & faculty fees$206,31959%
- Travel & lodging$39,86911%
- Food & beverage$20,7456%
- Education$2460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | 68 | $1,735,008 |
| AbbVie | 340 | $933,233 |
| Lilly USA, LLC | 292 | $176,673 |
| Janssen Research & Development, LLC | 22 | $67,257 |
| Eli Lilly | 34 | $42,357 |
| E.r. Squibb & Sons, L.L.C. | 35 | $41,160 |
| GSK | 31 | $34,812 |
| UCB, Inc. | 62 | $29,762 |
| Pfizer | 14 | $22,219 |
| Gilead | 3 | $19,089 |
| Genentech USA, Inc. | 17 | $16,211 |
| Merck | 12 | $8,458 |
| Amgen(2 entities) | 38 | $5,196 |
| Johnson & Johnson(2 entities) | 16 | $3,027 |
| Pfizer Pharmaceuticals LLC | 3 | $1,748 |
| AstraZeneca | 15 | $847 |
| Bristol Myers Squibb | 4 | $704 |
| Novartis | 12 | $600 |
| PBG Puerto Rico LLC | 13 | $562 |
| Sanofi | 8 | $377 |
| Mallinckrodt Hospital Products Inc. | 5 | $343 |
| Sanofi-aventis U.S. LLC | 2 | $167 |
| Genentech, Inc. | 2 | $160 |
| Boehringer Ingelheim | 6 | $138 |
| Sobi, Inc | 1 | $100 |
| Organon | 6 | $100 |
| ANI Pharmaceuticals, Inc. | 3 | $82 |
| EMD Serono, Inc. | 2 | $44 |
| Mallinckrodt Enterprises LLC | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,140,463 in reported general payments places this provider in the 95th percentile of 88 rheumatology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cimzia (2 Pack)Certolizumab Pegol | 41 | $260,551 |
| Humira(Cf) PenAdalimumab | 36 | $248,981 |
| Taltz AutoinjectorIxekizumab | 36 | $247,828 |
| RinvoqUpadacitinib | 32 | $208,088 |
| ProliaDenosumab | 63 | $110,194 |
| Cosentyx Sensoready PenSecukinumab | 14 | $104,878 |
| Enbrel SureclickEtanercept | 14 | $102,842 |
| Actemra ActpenTocilizumab | 18 | $84,447 |
| OtezlaApremilast | 12 | $57,664 |
| MethotrexateMethotrexate Sodium | 321 | $5,869 |
| Hydroxychloroquine Sulfate | 48 | $2,146 |
| Gabapentin | 194 | $2,103 |
| Pregabalin | 40 | $2,084 |
| SynthroidLevothyroxine Sodium | 12 | $1,492 |
| Prednisone | 132 | $1,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Cimzia (2 Pack) | $29,762 | $260,55141 claims |
| AbbVieRinvoq, Synthroid | $933,233 | $209,58044 claims |
| AmgenProlia, Otezla | $5,196 | $167,85975 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 rheumatology providers in Puerto Rico.
Other rheumatology in San Juan
- Carlos PantojasSan Juan$3.2M
- Radames Sierra ZoritaSan Juan$428K
- Paloma AlejandroSan Juan$347K
- Maria Chirino-SociasSan Juan$296K
- Yvonne FontSan Juan$193K
- Jose Ramirez VazquezSan Juan$171K
- Grissel RiosSan Juan$119K
- Irma Vazquez-SanabriaSan Juan$11K
- Valerie Marrero PereaSan Juan$10K
- Ariana Gonzalez-MelendezSan Juan$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.